Recently Launched!
Check out Investor Copilot custom GPT, which lets you enjoy ChatGPT functionality with recent financial information
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
[BPMC] Blueprint Medicines Corp - Financing Cash Flow / Sales
Data updated 2024-Mar-24 (Sunday)Note: Detailed Statistics for Financing Cash Flow / Sales in Cashflow Statement for Blueprint Medicines Corp [NASDAQ:BPMC] with frequency distribution chart that analyze trends & history . Financing Cash Flow / Sales or Revenue is expressed as a % for period. View Cashflow Statement for broader context
Share
Quarterly Financing Cash Flow / Sales values for Blueprint Medicines Corp are rounded to enhance readability
| 2023-Dec | 2023-Sep | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sep | |
|---|---|---|---|---|---|---|
| Financing Cash Flow / Sales | 21.6% | 174.0% | 9.2% | 8.4% | 6.4% | 576.8% |
| Sequential Quarter Growth | -87.6% | +1,790.8% | +9.9% | +30.4% | -98.9% | +18.8% |
| Quarter-on Quarter Growth | +236.1% | -69.8% | -98.1% | +954.1% | -56.6% | +1,465.7% |
Annual Financing Cash Flow / Sales values for Blueprint Medicines Corp are rounded to enhance readability
| 2023-Dec | 2022-Dec | 2021-Dec | 2020-Dec | 2019-Dec | 2018-Dec | |
|---|---|---|---|---|---|---|
| Financing Cash Flow / Sales | 47.8% | 275.4% | 24.9% | 343.1% | 42.9% | 6.7% |
| Year-on-Year Growth | -82.6% | +1,007.6% | -92.8% | +699.3% | +540.6% | -99.5% |
| 2-yr CAGR | +38.7% | -10.4% | -23.9% | +615.6% | -81.3% | -88.2% |
| 3-yr CAGR | -48.2% | +85.8% | +54.8% | -34.5% | -55.2% | -82.9% |
| 4-yr CAGR | +2.7% | +153.2% | -62.2% | -7.9% | -57.7% | |
| 5-yr CAGR | +48.1% | -25.8% | -44.6% | -23.9% |
Frequency distribution of quarterly Financing Cash Flow / Sales values from 2015-Mar-31 grouped into buckets. Latest Financing Cash Flow / Sales value is 21.6 as of 2023-Dec-31
Subsequent stock performance post earnings date till next announcement for Blueprint Medicines Corp mapped with quarterly Financing Cash Flow / Sales values reported at that time. Most recent value denoted with star
Select frequency and calculation type for Financing Cash Flow / Sales above for vertical axis in scatter chart. Additionally choose type of performance for horizontal axis
Bayesian (Conditional Probability) analysis for Blueprint Medicines Corp with subsequent post-earnings performance given Financing Cash Flow / Sales values. Analysis uses quarterly data and subsequent absolute performance. Most recent quarter is denoted with a star and corresponding partial performance is excluded from calculations
| Underperform (absolute perf.) | Outperform (absolute perf.) | |
|---|---|---|
| Financing Cash Flow / Sales - Low | 43% | 57% |
| Financing Cash Flow / Sales - Medium | 60% | 40% |
| Financing Cash Flow / Sales - High | 56% | 44% |
| Financing Cash Flow / Sales (Sequential growth %) - Low | 43% | 57% |
| Financing Cash Flow / Sales (Sequential growth %) - Medium | 83% | 17% |
| Financing Cash Flow / Sales (Sequential growth %) - High | 28% | 72% |
| Financing Cash Flow / Sales (QoQ growth %) - Low | 38% | 62% |
| Financing Cash Flow / Sales (QoQ growth %) - Medium | 41% | 59% |
| Financing Cash Flow / Sales (QoQ growth %) - High | 61% | 39% |
Related to Blueprint Medicines Corp
Information for Blueprint Medicines Corp
Current Detail : Recent daily/monthly performance & benchmark comparison
Historical Detail : Historical performance & related information using Time Machine
Financial Statements : Analyze Income Statement, Balance Sheet & Cashflow Statement and also compare with peers Currently Viewing
Bayesian Statement Classifier : Investigate historical financial statements to make probabalistic predictions using Artificial Intelligence
Anomaly Detection : Investigate unusual recent performance & technicals with historical context using AI
Historical Seasonality : Seasonal performance by calendar months
Technical History : Popular Technical indicator trends (RSI, MACD etc.)
Metric Deciles : Contextualizing recent performance & technical levels into historical decile buckets
Dollar Cost Averaging : Dollar Cost Average (DCA) over time in your portfolio
Moving Averages : Key Simple & Exponential Moving Averages
Historical Analogues : Insights from closest historical matches to recent performance using Artificial Intelligence
Chart Pattern Matching : Insights from similar historical charts to recent chart using Artificial Intelligence
News Stories : News stories on 2025-Jul-07 on Google
SEC Reports : Quarterly reports around 2025-Jul-07 on SEC Edgar
Compare Blueprint Medicines Corp with other assets
Market Performance : Recent performance across covered assets
Historical Performance : Prior & Subsequent performance across assets on a historical date
Market Technicals : Technical indicator levels across covered assets
Market Seasonality : Seasonal performance by calendar months across covered assets
Pair Correlations : Performance Correlations with other assets
Beta : Volatility relative to the broad market
Performance Comparison : Visually compare/benchmark performance with other assets over time
Side-by-Side Comparison : Contrast with other assets over time in a side-by-side presentation
Sector : Health Care sector performance which includes Blueprint Medicines Corp
Industry : Biotechnology industry performance which includes Blueprint Medicines Corp